Study shows success with ultrasound in the treatment of prostate carcinoma
Early data from the TACT pivotal study have now been presented at the annual conference of the American Urological Association (AUA) in San Francisco (California). TACT stands for TULSA-PRO® Ablation Clinical Trial.
What exactly is the TACT clinical study about?
The goal of TACT is to quantify exactly how treatment with TULSA-PRO® affects prostate-specific antigen. Prostate-specific antigen (PSA) is a protein that is only produced in the prostate. Its concentration is ten times higher in cancerous prostate tissue than in a healthy prostate. The aim of the study was to determine how many patients achieve a reduction in PSA level of more than 75 percent compared to the level that the patient had at the start of treatment.
Significant reduction in the PSA level after TULSA-PRO® prostate treatment
TULSA-PRO® is a new, minimally invasive procedure to ablate prostate tissue with high-intensity ultrasound. Using an imaging technique, it ensures precise ablation of the prostate. The goal is to minimize side effects such as impotence and incontinence. 115 localised prostate cancer patients with an average age of 64 years participated in the study at a total of 13 sites in the USA, Canada and Europe. Their average PSA level was 6.5 ng/ml. In his presentation at the AUA, prostate cancer expert and researcher Dr Laurence Klotz reported positive results: 109 out of 115 patients in the study reached the PSA endpoint after treatment, meaning that their PSA level fell by more than 95 percent following TULSA-PRO® procedure.
The current study also documents a comparatively low proportion of severe adverse events, confirming the results of a 2016 study by Chin et. al. published in the journal European Urology. Only seven percent of participants reported severe adverse effects such as infections. No rectal injuries or fistulas were found. In the further course of the study, it will also document trends in quality of life and frequently occurring side effects such as erectile dysfunction and urinary incontinence. As the standard evaluation period has not yet concluded, no reliable statements can be made about this yet. However, Dr Klotz seems to be encouraged by the available data.